ArticleFrontiers in pharmacology2022

Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer.

Tingfei Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.